Divesiran Phase 2 Hits Primary Endpoint with 88% Response Rate in PV, Phase 3 Next
SLN has more than doubled off its 52-week low of $4.19.
Summary
Silence Therapeutics' divesiran crushed its Phase 2 SANRECO primary endpoint in polycythemia vera, with 88% of treated patients achieving hematocrit control without phlebotomy versus 19% on placebo (p<0.0001). Both every-6-week and every-12-week dosing showed strong efficacy (93.8% and 81.3% response rates), and phlebotomy rates plummeted to 0.2 per patient versus 2.1 for placebo. Safety was clean, consistent with earlier trials. This follows positive Phase 1 data in June and a $100M ATM shelf activation in May — the company now has $72.1M in cash and a clear path to Phase 3. The data position divesiran as a potential best-in-class siRNA for PV, a blood cancer with high cardiovascular risk. A conference call at 8:00 a.m. ET will provide more color.
Updates
· SEC 8-K — The 8-K includes the press release and conference call presentation; Phase 3 trial evaluating divesiran Q12W vs. placebo is anticipated to initiate in 1H 2027.
At the time of this announcement, SLN was trading at $12.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $564.5M. The 52-week trading range was $4.19 to $12.31. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.